Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 21;40(1):202.
doi: 10.1186/s13046-021-02010-9.

Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer

Ramon Yarza  1   2 , Mateo Bover  3   4 , Maria Teresa Agulló-Ortuño  5   6   7   8 , Lara Carmen Iglesias-Docampo  3   4   9
Affiliations
Review

Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer

Ramon Yarza et al. J Exp Clin Cancer Res. .

Abstract

Nasopharyngeal carcinoma (NPC) represents a molecularly paradigmatic tumor given the complex diversity of environmental as well as host dependent factors that are closely implicated in tissue transformation and carcinogenesis. Epstein Barr Virus (EBV) plays a key role in tissue invasion, hyperplasia and malignant transformation. Therefore, EBV related oncoviral proteins such as Latent Membrane Protein family (LMP1, LMP2), Epstein Barr Nuclear Antigen 1 (EBNA1) and EBV related glycoprotein B (gB) are responsible for inducing intracellular signalling aberrations leading to sustained proliferation and further acquisition of NPC related invasive nature and metastatic potential.Dysregulation of proteasome signaling seems to be centrally implicated in oncoviral protein stabilization as well as in modulating tumor microenvironment. Different studies in vitro and in vivo suggest a potential role of proteasome inhibitors in the therapeutic setting of NPC. Furthermore, alterations affecting proteasome signalling in NPC have been associated to tumor growth and invasion, distant metastasis, immune exclusion and resistance as well as to clinical poor prognosis. So on, recent studies have shown the efficacy of immunotherapy as a suitable therapeutic approach to NPC. Nevertheless, novel strategies seem to look for combinatorial regimens aiming to potentiate immune recognition as well as to restore both primary and acquired immune resistance.In this work, our goal is to thoroughly review the molecular implications of proteasome dysregulation in the molecular pathogenesis of NPC, together with their direct relationship with EBV related oncoviral proteins and their role in promoting immune evasion and resistance. We also aim to hypothesize about the feasibility of the use of proteasome inhibitors as part of immunotherapy-including combinatorial regimens for their potential role in reversing immune resistance and favouring tumor recognition and eventual tumor death.

Keywords: Bortezomib; Epstein Barr virus; Immunotherapy; Nasopharyngeal carcinoma; Proteasome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflict of interest.

Figures

Fig. 1
Fig. 1
Diagram illustrating EBV associated nasopharyngeal damage and eventual carcinogenic transformation of NPC
Fig. 2
Fig. 2
Figure represents metabolic implications of EBV and proteasome dysregulation in NPC. Green arrows illustrate intracellular activation pathways. Red arrows show intracellular inhibitory pathways. Blue and black lines highlight initial and conclusive points of the pathways. A Biosignaling pathways associated to EBV infection and proteasome dysregulation in NPC cells. B Therapeutic implications of proteasome inhibitors in the molecular pathogenesis of NPC. **FBXO2 accounts for multimeric SKP1/Cul1/F-box
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Nakanishi Y, Wakisaka N, Kondo S, Endo K, Sugimoto H, Hatano M, Ueno T, Ishikawa K, Yoshizaki T. Progression of understanding for the role of Epstein-Barr virus and management of nasopharyngeal carcinoma. Cancer Metastasis Rev. 2017;36(3):435–447. doi: 10.1007/s10555-017-9693-x. - DOI - PMC - PubMed
    1. Bakkalci D, Jia Y, Winter JR, Lewis JE, Taylor GS, Stagg HR. Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence. J Glob Health. 2020;10(1):10405. doi: 10.7189/jogh.10.010405. - DOI - PMC - PubMed
    1. Bei J-X, Li Y, Jia W-H, Feng BJ, Zhou G, Chen LZ, Feng QS, Low HQ, Zhang H, He F, Tai ES, Kang T, Liu ET, Liu J, Zeng YX. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet. 2010;42(7):599–603. doi: 10.1038/ng.601. - DOI - PubMed
    1. Natasya Naili MN, Hasnita CH, Shamim AK, Hasnan J, Fauziah MI, Narazah MY, James A, Zulkiflee S, Nidzam MMT, Zilfalil BA. Chromosomal alterations in Malaysian patients with nasopharyngeal carcinoma analyzed by comparative genomic hybridization. Cancer Genet Cytogenet. 2010;203(2):309–312. doi: 10.1016/j.cancergencyto.2010.07.136. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources